A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index; 12 of the 30 sources its claims cite were checked for support.
Abstract
Phase 3 placebo-controlled trial of obeticholic acid in patients with PBC who had inadequate response to or unacceptable side effects with UDCA.
Overview
CoChat Summary
TL;DR
In the 12-month POISE phase 3 trial, obeticholic acid added to ursodiol or given as monotherapy improved the composite biochemical primary end point in patients with primary biliary cholangitis compared with placebo. Obeticholic acid also increased pruritus and serious adverse events.
Key findings
- The primary composite end point occurred in 46% of the 5–10-mg group and 47% of the 10-mg group versus 10% of the placebo group (P<0.001 for both comparisons).
- Alkaline phosphatase decreased by least-squares mean −113 U/L in the 5–10-mg group and −130 U/L in the 10-mg group versus −14 U/L with placebo (P<0.001 for both); total bilirubin changed by −0.02 and −0.05 mg/dL versus +0.12 mg/dL, respectively (P<0.001 for both).
- Noninvasive measures of liver fibrosis did not differ significantly between either obeticholic acid group and placebo at 12 months.
- Pruritus occurred in 56% of the 5–10-mg group and 68% of the 10-mg group versus 38% with placebo; serious adverse events occurred in 16%, 11%, and 4%, respectively.
Methods
- Randomized, double-blind, placebo-controlled, parallel-group, 12-month phase 3 trial at 59 sites in 13 countries; 217 patients underwent randomization and 216 received at least one dose, assigned 1:1:1 to placebo, obeticholic acid 5 mg with adjustment to 10 mg if applicable, or obeticholic acid 10 mg.
- Patients had primary biliary cholangitis with inadequate response to ursodiol or unacceptable ursodiol side effects; 93% received ursodiol as background therapy.
- Primary end point: alkaline phosphatase <1.67× upper limit of normal with ≥15% reduction from baseline and normal total bilirubin at 12 months; analyzed in the intention-to-treat population with Cochran–Mantel–Haenszel testing stratified by randomization factors, with missing values counted as nonresponse.
Limitations
- The paper states that results cover only 2 years of treatment, that the trial focused on surrogate biomarkers, imaging, and symptom end points with no statistical power to assess clinical outcomes, and that multiplicity adjustments were made only for the primary end point and not for secondary or exploratory analyses.
- Evident from the text: the open-label extension was not placebo-controlled, so longer-term durability and crossover findings are uncontrolled.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
10 Valid · 1 Not valid · 12 Not checked · 78 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“In addition, FXR regulates other pathways with direct antiinflammatory and antifibrotic effects. 13-15”
What the sources say
- Not checked — no full text of the sourcecites [13] source
- Disputedcites [14] sourceExperimental — accuracy not yet measured
The Discussion’s Systematic review says FXR agonists have indirect anti-fibrotic effects in animal models, contrary to the claim of direct anti-fibrotic effects. The cited passages do not describe direct anti-inflammatory effects or identify such pathways; page numbers are unavailable in our copy. (LLM, conf=0.84)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [15] source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In two 12-week phase 2 studies, daily doses of up to 50 mg of obeticholic acid resulted in reductions from baseline in levels of alkaline phosphatase and bilirubin that were significantly greater than those with placebo. 16”
What the sources say
- Partly supportedcites [16] sourceExperimental — accuracy not yet measured
The Abstract and Primary Efficacy End Point section report one three-month placebo-controlled trial in which daily obeticholic acid doses of 10–50 mg significantly reduced alkaline phosphatase versus placebo. The Secondary End Points section reports lower median conjugated bilirubin with obeticholic acid, but does not state that this reduction was statistically significant versus placebo. This paper therefore does not support the claim about two studies or the stated significance for bilirubin. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“However, dose-related increases in the incidence and severity of pruritus were evident, particularly at doses of more than 10 mg.”
What the sources say
- Supportedcites [16] source
The Adverse Events section says both pruritus incidence and severity were worse in the 25-mg and 50-mg groups than at 10 mg. It reports severe pruritus in 16%, 24%, and 37% of patients at 10, 25, and 50 mg, respectively. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In a large, international cohort analysis involving patients with primary biliary cholangitis, elevations in the alkaline phosphatase level were independently associated with a risk of liver transplantation or death that was 2.0 to 2.5 times as high as the risk associated with normal levels. 10”
What the sources say
- Partly supportedcites [10] sourceExperimental — accuracy not yet measured
The Statistical Analysis section (p. 3) says the analyses adjusted for age, sex, year of diagnosis, and UDCA therapy. The Results (p. 4) find higher alkaline phosphatase associated with greater risk of transplantation or death, but compare patients above 2.0 times the upper limit of normal with those at or below that threshold—not specifically with patients whose alkaline phosphatase was normal. The cited passages do not establish the claimed 2.0-to-2.5-fold risk relative to normal levels. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among the subgroup of patients who had transient elastography assessed (43%), obeticholic acid was not associated with significant reductions in this noninvasive measure of liver fibrosis at 12 months.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
45 more claims
Create a free account to see all 101 claims and every source verdict.
- Probably not a substantial claim. 22
- It may state two separate claims as one. 39
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Serum ALP dropped by 53.9% in the 10-mg group, 37.2% in the 50-mg group, and by only 0.8% in the placebo group.(160)”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [160]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Again, pruritus was the most important adverse event, leading to discontinuation of 38% of study subjects in the 50-mg arm.”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [160]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In an intention-to-treat analysis, biochemical response was met in 10% of the placebo group relative to 47% and 46% in the 10 mg and 5-10 mg dose-titrated OCA groups, respectively (p \0.0001 for both).”
From EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. (2017) · cites this paper as [131]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fatigue is not related to severity of liver disease, with the exception of very end-stage patients where it is the norm [221], and it is not responsive to UDCA or OCA therapy [6,131].”
From EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. (2017) · cites this paper as [131]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, OCA was not effective in decreasing PBC-induced liver fibrosis21,22.”
From SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis (2020) · cites this paper as [21]
Experimental — accuracy not yet measured
44 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237
Self-citationEASL Clinical Practice Guidelines: management of cholestatic liver diseases
European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.009 · Cited by 1,729
Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation
Lefebvre, P., Cariou, B., Lien, F., Kuipers, F., & Staels, B. (2009) · Physiological Reviews · doi:10.1152/physrev.00010.2008 · Cited by 1,678
Targeting bile‐acid signalling for metabolic diseases
Thomas, C., Pellicciari, R., Pruzanski, M., Auwerx, J., & Schoonjans, K. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2619 · Cited by 1,422
Self-citation(2011) · Encyclopedia of Cancer · doi:10.1007/978-3-642-16483-5_4730 · Cited by 1,240
Lindor, K. D., Gershwin, E. M., Poupon, R., Kaplan, M., Bergasa, N. V., & Heathcote, J. E. (2009) · Hepatology · doi:10.1002/hep.22906 · Cited by 1,099
Self-citationPellicciari, R., Fiorucci, S., Camaioni, E., Clerici, C., Costantino, G., Maloney, P. R., Morelli, A., Parks, D. J., & Willson, T. M. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm025529g · Cited by 743
Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis
Corpechot, C., Abenavoli, L., Rabahi, N., Chrétien, Y., Andréani, T., Johanet, C., Chazouillères, O., & Poupon, R. (2008) · Hepatology · doi:10.1002/hep.22428 · Cited by 646 · cited 3×
“(%) Death 1 (<1) Pruritus 4 (2) Other AEs 6 (3) Withdrew consent 5 (3) Other 4 (2) OLE = open-label extension a Denominator is based off the number randomized in each treatment group.”
BackgroundPrimary Biliary Cirrhosis Associated with HLA, IL12A, and IL12RB2 Variants
Hirschfield, G. M., Liu, X., Xu, C., Lu, Y., Xie, G., Lu, Y., Gu, X., Walker, E. J., Jing, K., Juran, B. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810440 · Cited by 594
Self-citationHirschfield, G. M., Mason, A., Luketic, V., Lindor, K., Gordon, S. C., Mayo, M., Kowdley, K. V., Vincent, C., Bodhenheimer, H. C., Parés, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.12.005 · Cited by 576
Self-citation
Research works printed but not linked: 1
- Bolier AR, 2012, Acta Gastroenterol Belg, 75, 399
Cited by
Items 201–300 of 1,138
Sex-related factors in autoimmune liver diseases
Schwinge, D., & Schramm, C. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-018-0715-8 · Cited by 66
Liu, Y., Guo, G., Zheng, L., Sun, R., Wang, X., Deng, J., Jia, G., Yang, C., Cui, L., Guo, C., et al. (2023) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002238 · Cited by 55
Noncanonical farnesoid X receptor signaling inhibits apoptosis and impedes liver fibrosis
Wang, H., Ge, C., Zhou, J., Guo, Y., Cui, S., Huang, N., Yan, T., Cao, L., Che, Y., Zheng, Q., et al. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.10.028 · Cited by 55
“Although OCAmay be effective against liver fibrosis in NASH [23,26], it had little effect on liver fibrosis in PBC patients [24,25], which may be partially explained by our findings that FXR agonists are not effective against DRs-engaged hepatocytes apoptosis, a key event in the pathological development of liver fibro…”
BackgroundReciprocal interactions between bile acids and gut microbiota in human liver diseases
Ikegami, T., & Honda, A. (2018) · Hepatology Research · doi:10.1111/hepr.13001 · Cited by 55
“Autoimmune(-Like)” drug and herb induced liver injury: new insights into molecular pathogenesis
Sebode, M., Schulz, L., & Lohse, A. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091954 · Cited by 47
“New drugs for PBC are pluripotent and aim at diverse mechanisms that are involved in bile acid metabolism and circulation, e.g., induction of excretory bile acid pumps.”
BackgroundInfluentialThe pathophysiological function of non-gastrointestinal farnesoid X receptor
Yan, N., Yan, T., Xia, Y., Hao, H., Wang, G., & Gonzalez, F. J. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107867 · Cited by 58
Management of metabolic-associated fatty liver disease: The diabetology perspective
Jeeyavudeen, M. S., Khan, S. K., Fouda, S., & Pappachan, J. M. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i1.126 · Cited by 54
Treatment of Pruritus Secondary to Liver Disease
Düll, M. M., & Kremer, A. E. (2019) · Current Gastroenterology Reports · doi:10.1007/s11894-019-0713-6 · Cited by 56
Managing portal hypertension in patients with liver cirrhosis
Sauerbruch, T., Schierwagen, R., & Trebicka, J. (2018) · F1000Research · doi:10.12688/f1000research.13943.1 · Cited by 61
Zhu, J.-B., Xu, S., Li, J., Song, J. H., Luo, B., Song, Y., Zhang, Z., Chen, Y., Xie, D., Yu, D., et al. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.09.009 · Cited by 53
Pharmacological interventions for primary biliary cholangitis
Saffioti, F., Gurusamy, K. S., Eusebi, L. H., Tsochatzis, E., Davidson, B. R., & Thorburn, D. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011648.pub2 · Cited by 53
Farnesoid X nuclear receptor agonists for the treatment of nonalcoholic steatohepatitis
Venetsanaki, V., Karabouta, Z., & Polyzos, S. A. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172661 · Cited by 52
Primary Biliary Cholangitis and Primary Sclerosing Cholangitis
Yokoda, R. T., & Carey, E. J. (2019) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000268 · Cited by 60
Recent advances in the management of pruritus in chronic liver diseases
Tajiri, K., & Shimizu, Y. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i19.3418 · Cited by 58
Modulating bile acid pathways and TGR5 receptors for treating liver and GI diseases
Malhi, H., & Camilleri, M. (2017) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2017.09.008 · Cited by 55
Gazda, J., Dražilová, S., Janíčko, M., & Jarčuška, P. (2021) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2021/9151525 · Cited by 61
Efficacy and safety of anti-hepatic fibrosis drugs
Damiris, K., Tafesh, Z., & Pyrsopoulos, N. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i41.6304 · Cited by 55
Hilscher, M. B., Kamath, P. S., & Eaton, J. E. (2020) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2020.01.015 · Cited by 68
Brown adipose tissue and regulation of human body weight
Harb, E., Kheder, O., Poopalasingam, G., Rashid, R., Srinivasan, A., & Izzi‐Engbeaya, C. N. (2022) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3594 · Cited by 55
“promising alternative strategy involves FXR agonism using obeticholic acid, although this is also limited by side‐effects.(79) Ingesting non‐pungent capsinoids to activate BAT may be the most tolerable approach,(71) but further studies are required to assess whether clinically significant weight loss can be achieved i…”
BackgroundMethodGlycochenodeoxycholate Promotes Liver Fibrosis in Mice with Hepatocellular Cholestasis
Hohenester, S. D., Kanitz, V., Kremer, A. E., Paulusma, C. C., Wimmer, R., Kühn, H., Denk, G., Horst, D. A., Elferink, R. P. J. O., & Beuers, U. H. (2020) · Cells · doi:10.3390/cells9020281 · Cited by 52
“In contrast, human chronic cholestatic liver diseases such as PBC are associated with minor elevations of ALT, as exemplified in a recent clinical trial cohort of PBC patients with insufficiently controlled disease, where mean baseline ALT was only marginally elevated (56 U/L) [37].”
BackgroundSelf-citationJohn, B. V., Schwartz, K., Levy, C., Dahman, B., Deng, Y., Martin, P., Taddei, T. H., & Kaplan, D. E. (2021) · Hepatology Communications · doi:10.1002/hep4.1720 · Cited by 51
“9 KPa,(5,10) nodularappearing liver, or the presence of portal hypertension.”
BackgroundInfluentialNevens, F., Trauner, M., & Manns, M. P. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.10.007 · Cited by 55
Self-citationOld and new treatments for primary biliary cholangitis
Chascsa, D. M. H., Carey, E. J., & Lindor, K. D. (2017) · Liver International · doi:10.1111/liv.13294 · Cited by 56
Self-citationGao, Q., Li, G., Zu, Y. X., Xu, Y., Wang, C., Xiang, D., He, W., Shang, T., Cheng, X., Liu, D., et al. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.117089 · Cited by 55
Schramm, C., Wedemeyer, H. H., Mason, A. L., Hirschfield, G. M., Levy, C., Kowdley, K. V., Milkiewicz, P., Janczewska, E., Malova, E. S., Sanni, J., et al. (2022) · JHEP Reports · doi:10.1016/j.jhepr.2022.100544 · Cited by 61
“study.(13) These findings indicate that occurrence of pruritus with FXR agonists in NASH(20,21,27) and PBC(12,13) could be related to the pathophysiology of these conditions.”
BackgroundInfluentialSelf-citationBile Acids, Liver Cirrhosis, and Extrahepatic Vascular Dysfunction
Sauerbruch, T., Hennenberg, M., Trebicka, J., & Beuers, U. H. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.718783 · Cited by 58
Self-citationKainuma, M., Takada, I., Makishima, M., & Sano, K. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19071898 · Cited by 52
“Recently, OCA has been studied in clinical trials for nonalcoholic steatohepatitis and primary biliary cholangitis [8,9].”
BackgroundPrevention of First Decompensation in Advanced Chronic Liver Disease
Mandorfer, M., & Simbrunner, B. (2021) · Clinics in Liver Disease · doi:10.1016/j.cld.2021.01.003 · Cited by 55
Signaling from Intestine to the Host: How Bile Acids Regulate Intestinal and Liver Immunity
Biagioli, M., & Carino, A. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_225 · Cited by 56
Efe, C., Taşçilar, K., Henriksson, I., Lytvyak, E., Alalkim, F., Trivedi, H., Eren, F., Eliasson, J., Beretta‐Piccoli, B. T., Fischer, J., et al. (2019) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000290 · Cited by 48
Self-citationLi, H. (2021) · Digestive and Liver Disease · doi:10.1016/j.dld.2021.07.006 · Cited by 51
Carino, A., Biagioli, M., Marchianò, S., Fiorucci, C., Bordoni, M., Roselli, R., Giorgio, C. D., Baldoni, M., Ricci, P., Monti, M. C., et al. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2020.158733 · Cited by 48
Zhuge, A., Li, S., Yuan, Y., Han, S., Xia, J., Wang, Q., Wang, S., Lou, P., Li, B., & Li, L. (2022) · Redox Biology · doi:10.1016/j.redox.2022.102582 · Cited by 54
Bile Acids in Cholestasis and its Treatment
Arab, J. P., Cabrera, D., & Arrese, M. A. (2017) · Annals of Hepatology · doi:10.5604/01.3001.0010.5497 · Cited by 52
Kennedy, L., Francis, H., Invernizzi, P., Venter, J., Wu, N., Carbone, M., Eric Gershwin, M., Bernuzzi, F., Franchitto, A., Alvaro, D., et al. (2019) · The FASEB Journal · doi:10.1096/fj.201802606r · Cited by 47
Self-citationFine‐Tuning of Sirtuin 1 Expression Is Essential to Protect the Liver From Cholestatic Liver Disease
Blokker, B. A., Maijo, M., Echeandia, M., Galduroz, M., Patterson, A. M., Ten, A., Philo, M., Schungel, R., Gutierrez‐de Juan, V., Halilbasic, E., et al. (2019) · Hepatology · doi:10.1002/hep.30275 · Cited by 46
“(35) FXR currently represents a promising target for therapeutic approaches to treat human cholestatic disease.(7-9) Regulation of FXR involves a dynamic deacetylation process coordinated by SIRT1(14) and is needed for FXR-DNA binding and target gene transcription, whereas the same process regulates FXR proteasomal de…”
BackgroundSelf-citationImmune system and cholangiocytes: A puzzling affair in primary biliary cholangitis
Ronca, V., Mancuso, C., Milani, C., Carbone, M., Oo, Y. H., & Invernizzi, P. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.5mr0320-200r · Cited by 46
Self-citationYokote, K., Yamashita, S., Arai, H., Araki, E., Matsushita, M., Nojima, T., Suganami, H., & Ishibashi, S. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01291-w · Cited by 52
Farnesoid X Receptor Agonists: A Promising Therapeutic Strategy for Gastrointestinal Diseases
Almeqdadi, M., & Gordon, F. D. (2023) · Gastro Hep Advances · doi:10.1016/j.gastha.2023.09.013 · Cited by 55
“21 Similar effects of OCA were seen in a long-term, randomized, double-blind, placebo-controlled phase 2 study in patients with PBC, which was followed up to 6 years.”
BackgroundMethodJohn, B. V., Khakoo, N. S., Schwartz, K. B., Aitchenson, G., Levy, C., Dahman, B. A., Deng, Y., Goldberg, D. S., Martin, P. B., Kaplan, D. E., et al. (2021) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001280 · Cited by 49
Management of Pruritus in Primary Biliary Cholangitis: A Narrative Review
Trivedi, H. D., Lizaola‐Mayo, B., Tapper, E. B., & Bonder, A. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.01.037 · Cited by 47
The pruritus of cholestasis: From bile acids to opiate agonists: Relevant after all these years
Bergasa, N. V. (2017) · Medical Hypotheses · doi:10.1016/j.mehy.2017.11.002 · Cited by 47
The history and future of bile acid therapies
Beuers, U. H., Bañales, J. M., Karpen, S. J., Keitel, V., Williamson, C., & Trauner, M. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.06.010 · Cited by 46
Self-citationSymptoms of PBC – Pathophysiology and management
Khanna, A., Leighton, J., Wong, L. L., & Jones, D. E. (2018) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2018.06.007 · Cited by 49
Self-citationRole of Bile Acids and the Biliary HCO3− Umbrella in the Pathogenesis of Primary Biliary Cholangitis
van Niekerk, J., Kersten, R., & Beuers, U. H. (2018) · Clinics in Liver Disease · doi:10.1016/j.cld.2018.03.013 · Cited by 43
Self-citationvan Golen, R. F., Olthof, P. B., Lionarons, D. A., Reiniers, M. J., Alles, L. K., Uz, Z., de Haan, L. R., Ergin, B., de Waart, D. R., Maas, M. A. W., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-33070-1 · Cited by 48
Contemporary epidemiology of primary biliary cholangitis
Colapietro, F., Bertazzoni, A., & Lleo, A. (2022) · Clinics in Liver Disease · doi:10.1016/j.cld.2022.06.001 · Cited by 43
Rekha, T. N., & Shin, D. (2023) · Pharmaceuticals · doi:10.3390/ph16030339 · Cited by 46
“Obeticholic Acid (2016) Obeticholic acid, in combination with ursodeoxycholic acid, is used in the treatment of primary biliary cholangitis [177].”
BackgroundNew developments in the treatment of primary biliary cholangitis – role of obeticholic acid
Jhaveri, M., & Kowdley, K. (2017) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s113052 · Cited by 43
“49 The results from the only Phase III clinical trial of OCA, 48 the PBC OCA International Study of Efficacy (POISE), were the basis for the US Food and Drug Administration’s approval of OCA in the treatment of PBC patients with incomplete response to UDCA.”
InfluentialSelf-citationTreatment of Fatigue in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis
Lee, J. Y., Danford, C. J., Trivedi, H. D., Tapper, E. B., Patwardhan, V. R., & Bonder, A. (2019) · Digestive Diseases and Sciences · doi:10.1007/s10620-019-5457-5 · Cited by 47
Ito, K., Okumura, A., Takeuchi, J. S., Watashi, K., Inoue, R., Yamauchi, T., Sakamoto, K., Yamashita, Y., Iguchi, Y., Une, M., et al. (2021) · Hepatology · doi:10.1002/hep.31712 · Cited by 47
Cirrhotic patients and older people
Carrier, P., Debette-Gratien, M., Jacques, J., & Loustaud-Ratti, V. (2019) · World Journal of Hepatology · doi:10.4254/wjh.v11.i9.678 · Cited by 47
Serum Autotaxin Is a Useful Disease Progression Marker in Patients with Primary Biliary Cholangitis
Joshita, S., Umemura, T., Usami, Y., Yamashita, Y., Norman, G. L., Sugiura, A., Yamazaki, T., Fujimori, N., Kimura, T., Matsumoto, A., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-26531-0 · Cited by 49
Obeticholic Acid for Primary Biliary Cholangitis
Floreani, A., Gabbia, D., & De Martin, S. (2022) · Biomedicines · doi:10.3390/biomedicines10102464 · Cited by 41
“The first approval of OCA was obtained following the results of a phase III trial that enrolled 216 patients [32], and demonstrated that about 59% of UDCA-non-responders benefitted from a one-year treatment with a combination of OCA and UDCA.”
BackgroundResultSelf-citationXiao, Y., Wang, Y., Liu, Y., Wang, W., Tian, X., Chen, S., Lu, Y., Du, J., & Cai, W. (2021) · Liver International · doi:10.1111/liv.14906 · Cited by 45
Gallucci, G. M., Hayes, C. M., Boyer, J. L., Barbier, O., Assis, D. N., & Ghonem, N. S. (2024) · Cells · doi:10.3390/cells13151296 · Cited by 40
“Obeticholic acid (OCA) is also FDA-approved for the treatment of PBC; however, its anti-cholestatic effect is modest and pruritus is a limiting side effect [5].”
BackgroundA Practical Review of Primary Biliary Cholangitis for the Gastroenterologist.
Onofrio, F. Q., Hirschfield, G. M., & Gulamhusein, A. F. (2019) · Europe PMC (PubMed Central) · Cited by 58
Self-citationGomez, E., Garcia Buey, L., Molina, E., Casado, M., Conde, I., Berenguer, M., Jorquera, F., Simón, M., Olveira, A., Hernández‐Guerra, M., et al. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16181 · Cited by 41
“7) Concomitant fibrates (n, %) 24 (20) Overlap syndrome (n, %) 12 (10) Liver biopsy (n, %) 77 (64.”
Sookoian, S. C., Flichman, D., Garaycoechea, M. E., Martino, J. S., Castaño, G. O., & Pirola, C. J. (2018) · Hepatology Communications · doi:10.1002/hep4.1184 · Cited by 43
Evaluation and Management of Pruritus in Primary Biliary Cholangitis
Düll, M. M., & Kremer, A. E. (2022) · Clinics in Liver Disease · doi:10.1016/j.cld.2022.06.009 · Cited by 46
Attia, Y. M., Tawfiq, R. A., Gibriel, A. A., Ali, A. A., Kassem, D. H., Hammam, O. A., & Elmazar, M. M. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114497 · Cited by 42
Carino, A., Biagioli, M., Marchianò, S., Scarpelli, P., Zampella, A., Limongelli, V., & Fiorucci, S. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.02.033 · Cited by 44
Semisynthetic bile acids: a new therapeutic option for metabolic syndrome
Lazarević, S., Đanić, M., Goločorbin-Kon, S., Al‐Salami, H., & Mikov, M. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104333 · Cited by 42
Bile acid metabolism and FXR-mediated effects in human cholestatic liver disorders
Molinaro, A., & Marschall, H. (2022) · Biochemical Society Transactions · doi:10.1042/bst20210658 · Cited by 47
Self-citationBile Acid Metabolism in Health and Disease
Li, T., & Chiang, J. Y. L. (2020) · Wiley eBooks · doi:10.1002/9781119436812.ch23 · Cited by 42
The Role of Bile Acids in the Human Body and in the Development of Diseases
Shulpekova, Y. O., Жаркова, М. С., Tkachenko, P. E., Тихонов, И. Н., Stepanov, A. A., Sinitsyna, A. A., Izotov, A., Butkova, T. V., Shulpekova, N. V., Лапина, Н. В., et al. (2022) · Molecules · doi:10.3390/molecules27113401 · Cited by 49
Xiang, J., Yang, G., Ma, C., Wei, L., Wu, H., Zhang, W., Tao, X., Jiang, L., Liang, Z., Kang, L., et al. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15429 · Cited by 46
“In 2016, obeticholic acid (OCA), a FXR agonist, was found to decrease serum alkaline phosphatase (AP) levels in CLD patients and was approved by the food and drug administration (FDA, USA) for UDCA non-responders (Hirschfield et al., 2015; Nevens et al., 2016).”
BackgroundTerziroli Beretta-Piccoli, B., Stirnimann, G., Mertens, J., Semela, D., Zen, Y., Mazzucchelli, L., Voreck, A., Kolbus, N., Merlo, E., Di Bartolomeo, C., et al. (2021) · Journal of Autoimmunity · doi:10.1016/j.jaut.2020.102578 · Cited by 39
Mayo, M. J., Vierling, J. M., Bowlus, C. L., Levy, C., Hirschfield, G. M., Neff, G. W., Galambos, M. R., Gordon, S. C., Borg, B. B., Harrison, S. A., et al. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17755 · Cited by 39
Self-citationEngel, B., Taubert, R., Jaeckel, E., & Manns, M. P. (2020) · Liver International · doi:10.1111/liv.14378 · Cited by 43
Newer Approaches to the Management of Pruritus in Cholestatic Liver Disease
Düll, M. M., & Kremer, A. E. (2020) · Current Hepatology Reports · doi:10.1007/s11901-020-00517-x · Cited by 46
Clinical Management of Primary Biliary Cholangitis—Strategies and Evolving Trends
Gao, L., Wang, L., Woo, E., He, X., Yang, G., Bowlus, C., Leung, P. S. C., & Gershwin, M. E. (2020) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-019-08772-7 · Cited by 39
Self-citationCrosstalk between Gut Microbiota and Bile Acids in Cholestatic Liver Disease
Shi, Q., Yuan, X., Zeng, Y., Wang, J., Zhang, Y., Chen, X., & Li, L. (2023) · Nutrients · doi:10.3390/nu15102411 · Cited by 42
UK-Wide Multicenter Evaluation of Second-line Therapies in Primary Biliary Cholangitis
Abbas, N., Culver, E. L., Thorburn, D., Halliday, N., Crothers, H., Dyson, J. K., Phaw, A., Aspinall, R., Khakoo, S. I., Kallis, Y., et al. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2022.07.038 · Cited by 39
Self-citationAntifibrotics in liver disease: are we getting closer to clinical use?
Bansal, M. B., & Chamroonkul, N. (2018) · Hepatology International · doi:10.1007/s12072-018-9897-3 · Cited by 45
Treatment of primary biliary cholangitis ursodeoxycholic acid non‐responders: A systematic review
Suraweera, D., Rahal, H., Jimenez, M., Viramontes, M., Choi, G., & Saab, S. (2017) · Liver International · doi:10.1111/liv.13477 · Cited by 38
The enhanced liver fibrosis (ELF) test in diagnosis and management of liver fibrosis
Day, J. W., & Rosenberg, W. M. (2018) · British Journal of Hospital Medicine · doi:10.12968/hmed.2018.79.12.694 · Cited by 42
Biochemical and plasma lipid responses to pemafibrate in patients with primary biliary cholangitis
Joshita, S., Umemura, T., Yamashita, Y., Sugiura, A., Yamazaki, T., Fujimori, N., Matsumoto, A., & Tanaka, E. (2019) · Hepatology Research · doi:10.1111/hepr.13361 · Cited by 38
Primary biliary cholangitis drug evaluation and regulatory approval: Where do we go from here?
Jones, D. E. J., Beuers, U., Bonder, A., Carbone, M., Culver, E., Dyson, J., Gish, R. G., Hansen, B. E., Hirschfield, G., Jones, R., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000000864 · Cited by 38
“Mean baseline ALP Mean baseline ALP:ULN ratio OCA phase 2 [24] 287 ± 164 2.2 OCA phase 3 ( “ POISE ” ) [16] 326 ± 196 2.5 OCA phase 3 confirmatory ( “ COBALT ” ) [25] 490 ± 285 3.8 Bezafibrate phase 3 [17] 243 ± 114 1.8 Elafibranor phase 3 ( “ ELATIVE ” ) [21] 322 ± 151 3.1 Seladelpar phase 3 ( “…”
BackgroundInfluentialSelf-citationCurrent and new pharmacotherapy options for non-alcoholic steatohepatitis
Sumida, Y., Yoneda, M., Ogawa, Y., Yoneda, M., Okanoue, T., & Nakajima, A. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1744564 · Cited by 38
Efficacy and safety of obeticholic acid in liver disease—A systematic review and meta-analysis
Kulkarni, A. V., Tevethia, H. V., Arab, J. P., Cândia, R., Premkumar, M., Kumar, P., Sharma, M., Reddy, D. N., & Padaki, N. R. (2021) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2021.101675 · Cited by 43
Genetic determinants of cholangiopathies: Molecular and systems genetics
Reichert, M., Hall, R. A., Krawczyk, M. J., & Lammert, F. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.07.029 · Cited by 40
Review article: pathophysiology and management of primary biliary cholangitis
Leung, K. K., Deeb, M., & Hirschfield, G. M. (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16023 · Cited by 40
Self-citationPhotosensitized Gold-Catalyzed Cross-Couplings of Aryl Bromides
Wu, J., Guo, F., Yi, C., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.4c14501 · Cited by 38
Primary Biliary Cholangitis: advances in management and treatment of the disease
Invernizzi, P., Floreani, A., Carbone, M., Marzioni, M., Craxì, A., Muratori, L., Gentilucci, U. V., Gardini, I., Gasbarrini, A., Kruger, P., et al. (2017) · Digestive and Liver Disease · doi:10.1016/j.dld.2017.05.001 · Cited by 48
Self-citationDiagnosis and treatment of primary biliary cholangitis
Laschtowitz, A., de Veer, R. C., der Meer, A. J. V., & Schramm, C. (2020) · United European Gastroenterology Journal · doi:10.1177/2050640620919585 · Cited by 44
Epigenetics in the primary biliary cholangitis and primary sclerosing cholangitis
Cheung, A., LaRusso, N., Gores, G., & Lazaridis, K. (2017) · Seminars in Liver Disease · doi:10.1055/s-0037-1603324 · Cited by 37
Montaño‐Loza, A. J., & Corpechot, C. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.06.062 · Cited by 44
Inflammation: Cause or consequence of chronic cholestatic liver injury
Woolbright, B. L. (2020) · Food and Chemical Toxicology · doi:10.1016/j.fct.2020.111133 · Cited by 44
Jones, D., Carbone, M., Invernizzi, P., Little, N., Nevens, F., Swain, M. G., Wiesel, P., & Levy, C. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000057 · Cited by 37
“[31,33] The only trial to date that assessed the effects of OCA treatment on fatigue did not show alleviation of symptoms.[8] Liver transplantation, a last resort for some patients with end-stage PBC and not a treatment option for fatigue alone, has been reported to result in some alleviation and reduction in risk of…”
BackgroundSelf-citationvan Zutphen, T., Stroeve, J. H. M., Yang, J., Bloks, V. W., Jurdzinski, A., Roelofsen, H., Huijkman, N., van Dijk, T. H., Vonk, R. J., van Deursen, J., et al. (2019) · Journal of Lipid Research · doi:10.1194/jlr.m094508 · Cited by 40
Obeticholic acid in primary biliary cholangitis: where we stand
Manne, V., & Kowdley, K. V. (2019) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000525 · Cited by 44
Self-citationToward solving the etiological mystery of primary biliary cholangitis
Tanaka, A., Leung, P. S. C., Young, H. A., & Gershwin, M. E. (2017) · Hepatology Communications · doi:10.1002/hep4.1044 · Cited by 37
“(18-20) Recently, obeticholic acid, a selective ligand of the farnesoid X receptor, was approved for patients who are refractory to UDCA.”
Li, Q., Li, M., Li, F., Zhou, W., Dang, Y., Zhang, L. R., & Ji, G. (2020) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2020.112896 · Cited by 40
Gao, R. Y., Shearn, C. T., Orlicky, D. J., Battista, K. D., Alexeev, E. E., Cartwright, I. M., Lanis, J. M., Kostelecky, R. E., Ju, C., Colgan, S. P., et al. (2021) · Mucosal Immunology · doi:10.1038/s41385-020-00347-6 · Cited by 37
He, C., Yang, Y., Zheng, K., Chen, Y., Liu, S., Li, Y., Han, Q., Zhao, R. C., Wang, L., & Zhang, F. (2021) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622321993442 · Cited by 44
Reig, A., Álvarez-Navascués, C., Vergara, M., Gómez-Domínguez, E., Gallego-Moya, A., Pérez-Medrano, I. M., Fábrega, E., Hernández-Guerra, M., Berenguer, M., Estevez, P., et al. (2021) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001343 · Cited by 35
“OCA in addition to UDCA (6,8) or in monotherapy (7,8) results in biochemical improvement in liver parameters such as alkaline phosphatase (ALP) and bilirubin, which are associated with the prognosis of the disease, and has demonstrated efficacy in phase II (6,7) and III placebo-controlled (8) trials.”
BackgroundResultSelf-citationXu, W., Lu, C., Zhang, F., Shao, J., Yao, S., & Zheng, S. (2017) · The FEBS Journal · doi:10.1111/febs.13956 · Cited by 36
Antigen-Specific Immunotherapy for Treatment of Autoimmune Liver Diseases
Richardson, N., Ng, S. T. H., & Wraith, D. C. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01586 · Cited by 40
“only 8% of patients treated with UDCA alone (137, 138).”
BackgroundTreatment of primary sclerosing cholangitis
Floreani, A., & Martin, S. D. (2021) · Digestive and Liver Disease · doi:10.1016/j.dld.2021.04.028 · Cited by 47
Self-citation
Metadata
- Authors
- Nevens, F., Andreone, P., Mazzella, G., Strasser, S. I., Bowlus, C., Invernizzi, P., Drenth, J. P. H., Pockros, P. J., Regula, J., Beuers, U., Trauner, M., Jones, D. E., Floreani, A., Hohenester, S., Luketic, V., Shiffman, M., van Erpecum, K. J., Vargas, V., Vincent, C., Hirschfield, G. M., Shah, H., Hansen, B., Lindor, K. D., Marschall, H.-U., Kowdley, K. V., Hooshmand-Rad, R., Marmon, T., Sheeron, S., Pencek, R., MacConell, L., Pruzanski, M., & Shapiro, D.
- Affiliations
- University of Padua (IT)
- Humanitas University (IT)
- University Health Network (CA)
- ORCID
- Nevens, Frederik
- Mazzella, Giuseppe
- Strasser, Simone I.
- Bowlus, Christopher
- Invernizzi, Pietro
- Drenth, Joost P.H.
- Pockros, Paul J.
- Beuers, Ulrich
- Trauner, Michael
- Jones, David E.
- Floreani, Annarosa
- Hohenester, Simon
- Luketic, Velimir
- Shiffman, Mitchell
- Vincent, Catherine
- Hirschfield, Gideon M.
- Shah, Hemant
- Hansen, Bettina
- Lindor, Keith D.
- Marschall, Hanns-Ulrich
- Kowdley, Kris V.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-08-18
- Volume
- 375
- Issue
- 7
- Pages
- 631-643
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2518389324
- Cited by
- 1,131
- References
- 33
- Citations by year
- 2026: 91 · 2025: 118 · 2024: 108 · 2023: 100 · 2022: 123 · 2021: 115 · 2020: 123 · 2019: 111 · 2018: 129 · 2017: 97 · 2016: 14
- FWCI
- 84.82
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Lirias (submittedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion, other-oa)
- Radboud Repository (Radboud University) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
- Funders
- Intercept Pharmaceuticals
- National Institute for Health and Care Research (NF-SI-0513-10091)
- Medical Research Council (MR/L001489/1)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Keywords
- obeticholic acid, primary biliary cirrhosis, farnesoid X receptor agonist, ursodeoxycholic acid, alkaline phosphatase, total bilirubin, liver fibrosis, pruritus, liver transplantation, liver cirrhosis, drug safety, dose comparison, noninvasive fibrosis assessment
- MeSH terms
- Adult, Aged, Alkaline Phosphatase, Bile Acids and Salts, Chenodeoxycholic Acid, Double-Blind Method, Female, Fibroblast Growth Factors, Humans, Liver Cirrhosis, Liver Cirrhosis, Biliary, Male, Middle Aged, Pruritus, Bone Density
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.